KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) EPS (Weighted Average and Diluted) (2020 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed EPS (Weighted Average and Diluted) for 4 consecutive years, with -$11.96 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, EPS (Weighted Average and Diluted) rose 75.6% year-over-year to -$11.96, compared with a TTM value of -$18.37 through Dec 2023, up 63.41%, and an annual FY2025 reading of -$5.64, up 46.49% over the prior year.
  • EPS (Weighted Average and Diluted) was -$11.96 for Q4 2023 at Ginkgo Bioworks Holdings, down from -$6.21 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.05 in Q4 2020 and bottomed at -$49.01 in Q4 2022.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$5.83, with a median of -$0.39 recorded in 2022.
  • The sharpest move saw EPS (Weighted Average and Diluted) crashed 3950.41% in 2022, then skyrocketed 78.05% in 2023.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.05 in 2020, then plummeted by 2494.08% to -$1.21 in 2021, then plummeted by 3950.41% to -$49.01 in 2022, then surged by 75.6% to -$11.96 in 2023.
  • Business Quant data shows EPS (Weighted Average and Diluted) for DNA at -$11.96 in Q4 2023, -$6.21 in Q3 2023, and -$0.09 in Q2 2023.